- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
中国第三款 CanSino 腺病毒单针疫苗。第三期数据(2月8日)：总效力 74.8%， 没血栓。已经成为多个国家疫苗护照
- 主题发起人 向问天
- 开始时间
- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
康熙诺疫苗获匈牙利批准紧急使用。
MON MAR 22, 2021 / 8:09 AM EDT
(Reuters) - Hungary is the first European Union (EU) country to approve for emergency use China's CanSino Biologics coronavirus vaccine and CoviShield, the Indian version of the AstraZeneca shot, the Hungarian surgeon general said on Monday.
New infections are surging in Hungary in a third wave of the pandemic, even as vaccine import and usage rates are among the highest in the EU with the country using Chinese and Russian vaccines as well as Western ones.
If both new vaccines are also approved for mass use by the National Health Centre, Hungary will have seven sources to procure vaccines from. It was unclear when and in what quantity Hungary planned to deploy the newly authorised vaccines, or how it planned to buy them.
MON MAR 22, 2021 / 8:09 AM EDT
Hungary approves new Chinese vaccine for emergency use
(Reuters) - Hungary is the first European Union (EU) country to approve for emergency use China's CanSino Biologics coronavirus vaccine and CoviShield, the Indian version of the AstraZeneca shot, the Hungarian surgeon general said on Monday.
New infections are surging in Hungary in a third wave of the pandemic, even as vaccine import and usage rates are among the highest in the EU with the country using Chinese and Russian vaccines as well as Western ones.
If both new vaccines are also approved for mass use by the National Health Centre, Hungary will have seven sources to procure vaccines from. It was unclear when and in what quantity Hungary planned to deploy the newly authorised vaccines, or how it planned to buy them.
- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
ä¸åå¤äº¤é¨åæ康æå±å¦»åè¦æ±éæ¾åæèï¼
6æ24æ¥ï¼è¶ç«å 表示ï¼æ£å¦åº·æå±å¦»åæ說çï¼å æ¿å¤§å¸æ³é¨é·ææ¬å¨ä»»ä½æå»çµæ¢åæèæ¡çå¼æ¸¡ç¨åºãé說æå æ¿åºå¨åæèäºä»¶ä¸æ¯å¯ä»¥æ ¹æèªå·±çæ³å¾ç§å¬å·æ³çãæåå次æ¦ä¿å æ¹å實å°éæ³æ²»ç²¾ç¥ï¼ç«å³éæ¾åæè女士ï¼ä¸¦è®å¥¹å¹³å®åå°ä¸åã以å¨çè¦éç¡æ¬å¤©ä¸å¤§äºï¼æ¯æ¥æ´æ°ï½ï½æ¡è¿è¨é±ï¼https://bit.ly/2XNJUxg
youtube.com
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
3 hr 42 min ago
Chile's Institute of Public Health authorized the emergency use of the new CanSino Biologics vaccine on Wednesday, according to a statement from the Health Ministry.
President Sebastián Piñera highlighted the need for the acquisition of 1.8 million single doses from the Chinese-Canadian laboratory CanSino, and said the vaccinations would take place between April and May.
Chile already uses vaccines from Sinovac, Pfizer/BioNTech and Oxford/AstraZeneca. It has vaccinated 7,111,354 people so far, of which 4,192,320 have received the complete dosage.
There have been 1,043,022 confirmed cases of Covid-19 and 23,796 deaths associated with the disease, according to the latest figures by Chilean health authorities.
Chile authorizes 1.8 million doses of CanSino vaccine
From CNN's Florencia Trucco and Jaide GarciaChile's Institute of Public Health authorized the emergency use of the new CanSino Biologics vaccine on Wednesday, according to a statement from the Health Ministry.
President Sebastián Piñera highlighted the need for the acquisition of 1.8 million single doses from the Chinese-Canadian laboratory CanSino, and said the vaccinations would take place between April and May.
Chile already uses vaccines from Sinovac, Pfizer/BioNTech and Oxford/AstraZeneca. It has vaccinated 7,111,354 people so far, of which 4,192,320 have received the complete dosage.
There have been 1,043,022 confirmed cases of Covid-19 and 23,796 deaths associated with the disease, according to the latest figures by Chilean health authorities.
- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
Health 10:48, 16-Apr-2021
CanSino says no serious blood clots from its vaccine
Updated 11:21, 16-Apr-2021
CanSino said in a statement on April 14 that no serious blood clot cases had been reported in people inoculated with its COVID-19 vaccine. /CFP
China's CanSino Biologics Inc. said on Wednesday that no serious blood clot cases have been reported in about one million people inoculated with its single-dose COVID-19 vaccine, after noting concerns over blood clots cases reported with two other vaccines developed with the similar vaccine technology – adenoviral vectors.
U.S. federal health agencies recommended on Tuesday a pause of the use of a one-shot vaccine from Johnson & Johnson after six women had developed rare blood clots, and European regulators last week said they had found a possible link between AstraZeneca's vaccine and a similar rare blood clotting problem.
Adenovirus-vectored vaccines use adenoviruses as the vector to deliver DNA instructions for human cells to produce part of the coronavirus that can spur the immune system to recognize SARS-CoV-2.
Though also an adenovirus-vectored vaccine, CanSino's Ad5-nCoV vaccine is developed based on a common cold-causing virus known as Ad5, while AstraZeneca uses a virus found in Chimpanzee and the Johnson & Johnson uses a human adenovirus known as Ad26.
CanSino's vaccine has been approved in China, Hungary, Chile, Mexico and Pakistan.
The company said it will closely monitor the situation and make further announcements in accordance with the rules governing the listing of securities on the Stock Exchange of Hong Kong Limited at the appropriate time.
(With input from Reuters)
news.cgtn.com
CanSino says no serious blood clots from its vaccine
Updated 11:21, 16-Apr-2021
CanSino said in a statement on April 14 that no serious blood clot cases had been reported in people inoculated with its COVID-19 vaccine. /CFP
China's CanSino Biologics Inc. said on Wednesday that no serious blood clot cases have been reported in about one million people inoculated with its single-dose COVID-19 vaccine, after noting concerns over blood clots cases reported with two other vaccines developed with the similar vaccine technology – adenoviral vectors.
U.S. federal health agencies recommended on Tuesday a pause of the use of a one-shot vaccine from Johnson & Johnson after six women had developed rare blood clots, and European regulators last week said they had found a possible link between AstraZeneca's vaccine and a similar rare blood clotting problem.
Adenovirus-vectored vaccines use adenoviruses as the vector to deliver DNA instructions for human cells to produce part of the coronavirus that can spur the immune system to recognize SARS-CoV-2.
Though also an adenovirus-vectored vaccine, CanSino's Ad5-nCoV vaccine is developed based on a common cold-causing virus known as Ad5, while AstraZeneca uses a virus found in Chimpanzee and the Johnson & Johnson uses a human adenovirus known as Ad26.
CanSino's vaccine has been approved in China, Hungary, Chile, Mexico and Pakistan.
The company said it will closely monitor the situation and make further announcements in accordance with the rules governing the listing of securities on the Stock Exchange of Hong Kong Limited at the appropriate time.
(With input from Reuters)
CanSino says no serious blood clots from its vaccine
China's CanSino Biologics Inc. said on Wednesday that no serious blood clot cases have been reported in about one million people inoculated with its single-dose COVID-19 vaccine, after noting concerns over blood clots cases reported with two other vaccines developed with the similar vaccine...
news.cgtn.com
最后编辑:
